News
BioTek Instruments, Inc. Develops Automation Technology to Aid in Blood Banking Tests
June 27, 2007
The Galileo Echo instrument was recently cleared by the FDA for marketing in the United States, and also received a CE mark, along with its associated reagents, for distribution in Europe. “Immucor and BioTek have forged a strong partnership for over fifteen years, which is key to producing beneficial products that seamlessly fuse our respective skills and expertise,” noted Adam Alpert, Vice President of BioTek Instruments. “We congratulate Immucor on the recent clearance of the Galileo Echo system, and we look forward to the results of our mutually successful projects.”
BioTek Instruments, Inc., headquartered in Winooski, VT, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. The BioTek Instruments, Inc. instrumentation is used to accelerate the drug discovery process, to advance discoveries in genomics and proteomics, and to aid in the advancement of life science research.
Founded in 1982, Immucor, Inc. manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of their market segments.
For further information, contact:
Chere Griffin
Shaw & Todd Advertising and Marketing Communications
908-668-1106 x15
cgriffin@shawtodd.com